OR WAIT null SECS
August 13, 2019
Using Alternating Tangential Flow in a 3000-L perfusion bioreactor, the company expects to reduce production time by up to 30%
August 08, 2019
The company has launched new services for mammalian cell bank manufacturing under GMP conditions.
August 02, 2019
As vaccines gain prominence within pharma, there is an expectation that specialized CDMO services will provide opportunities.
Complex and potent molecules demand greater technical and regulatory expertise to ensure safe handling.
July 17, 2019
Catalent Biologics has entered into a long-term strategic agreement to develop and manufacture an AveXis gene therapy treatment for spinal muscular atrophy (SMA), Zolgensma.
July 03, 2019
Metabolic-disease biotech Amicus Therapeutics announced a manufacturing agreement with Catalent’s Paragon Gene Therapy unit for gene therapy manufacturing.
July 02, 2019
Amicus Therapeutics has entered into a strategic gene therapy development and manufacturing collaboration with Brammer Bio, which is a part of Thermo Fisher Scientific.
The increasing growth in the cell- and gene-therapy markets is inspiring CDMOs to expand their services in this emerging biologic drug arena.
June 07, 2019
The $10-million investment will include a 500-L single-use perfusion bioreactor and seven patented downstream processing units.
June 05, 2019
CDMO iBio introduced cGMP sterile fill/finish services at its facility in Texas.